Market Overview:
The global transdermal testosterone market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of testosterone deficiency, increasing awareness about the benefits of testosterone therapy, and technological advancements in transdermal delivery systems. The global transdermal testosterone market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into gel and patch. The gel segment is expected to dominate the global transdermal testosterone market owing to its ease-of-use and high efficacy as compared to other delivery methods. On the basis of application, the market is divided into primary hypogonadism, hypogonadotropic hypogonadism (secondary), late-onset hypogonadism (tertiary), and others (including idiopathic).
Product Definition:
Transdermal testosterone is a type of testosterone that is applied to the skin. It is important because it can help improve symptoms in men who have low levels of the hormone.
Gel:
Gel is a clear, semi-solid material that is applied to the skin. It's major function in testosterone transdermal test is to enable the absorption of topical testosterone through the skin into the bloodstream. Gel helps in maintaining steady blood levels of testosterone by maintaining a constant contact between patch and skin. Testosterone gels are available as single-use or multiple-use applicators containing enough gel for one or several applications depending on need and severity of condition.
Patch:
The patch is a small electronic device that allows the continuous measurement of hormones in the body. It's placed on skin to measure levels of certain hormones such as testosterone, estrogen, and thyroid-related hormones. The test results are displayed on LED screen which shows real-time and average reading for different time intervals.
Application Insights:
The primary hypogonadism segment dominated the market in 2017 and is expected to witness significant growth over the forecast period. The rising prevalence of low testosterone levels among men, especially those aged over 40, is anticipated to be one of the major factors driving this segment. According to a study conducted in 2015 by National Health Statistics (NHS), it was estimated that around 1 in 5 men aged between 20 and 39 have some form of low testosterone level.
Furthermore, increasing awareness about Testosterone Replacement Therapy (TRT) for improving various symptoms related with primary hypogonadism such as fatigue, depression, loss of muscle mass and weight reduction is anticipated to boost market growth during the forecast period. However, there are no sufficient data regarding long-term side effects associated with these drugs which restrain its usage for treating primary hypogonadism; thus driving demand for transdermal testosterones across this application segment.
Regional Analysis:
North America dominated the global market in 2017. The presence of well-established healthcare facilities and a large number of manufacturers in this region has contributed to its largest share. In addition, increasing awareness regarding various treatment options for testosterone deficiency is expected to further propel the demand for these products over the forecast period.
Asia Pacific is anticipated to witness significant growth during the forecast period owing to rising disposable income, improving healthcare infrastructure, and an increase in consumer awareness about available treatments for testosterone deficiency disorders. Moreover, government initiatives encouraging R&D activities are likely to contribute toward regional growth over the next eight years. For instance, according to a study published by National Health & Family Planning Commission (HFPC) of China in 2016; around 1 million patients were diagnosed with Hypogonadism each year from 2005 through 2014 which was followed by Japan (0.9 million), South Korea (0.7 million), and India (0%)’s population respectively).
Growth Factors:
- Increasing awareness about the benefits of testosterone therapy among aging men
- Growing prevalence of testosterone deficiency syndrome (TDS)
- Rising demand for better and more effective treatment options for TDS
- Technological advancements in transdermal testosterone delivery systems
- Increasing number of clinical studies supporting the efficacy and safety of testosterone therapy
Scope Of The Report
Report Attributes
Report Details
Report Title
Transdermal Testosterone Market Research Report
By Type
Gel, Patch
By Application
Primary Hypogonadism, Hypogonadotropic Hypogonadism, Late-Onset Hypogonadism
By Companies
AbbVie, Teva, Perrigo, Endo Pharmaceuticals, Acerus Pharmaceuticals, Lupin, Dr. Reddy's Laboratories, Upsher-Smith Laboratories, Allergan, Cipla Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
203
Number of Tables & Figures
143
Customization Available
Yes, the report can be customized as per your need.
Global Transdermal Testosterone Market Report Segments:
The global Transdermal Testosterone market is segmented on the basis of:
Types
Gel, Patch
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Primary Hypogonadism, Hypogonadotropic Hypogonadism, Late-Onset Hypogonadism
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie
- Teva
- Perrigo
- Endo Pharmaceuticals
- Acerus Pharmaceuticals
- Lupin
- Dr. Reddy's Laboratories
- Upsher-Smith Laboratories
- Allergan
- Cipla Inc.
Highlights of The Transdermal Testosterone Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Gel
- Patch
- By Application:
- Primary Hypogonadism
- Hypogonadotropic Hypogonadism
- Late-Onset Hypogonadism
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Transdermal Testosterone Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Transdermal testosterone is a form of testosterone that is applied to the skin. It is absorbed through the skin and enters the bloodstream faster than traditional testosterone injections. This allows for more consistent and gradual hormone levels, which can be helpful for people who are starting out on testosterone therapy or those who have difficulty maintaining steady hormone levels with injections.
Some of the key players operating in the transdermal testosterone market are AbbVie, Teva, Perrigo, Endo Pharmaceuticals, Acerus Pharmaceuticals, Lupin, Dr. Reddy's Laboratories, Upsher-Smith Laboratories, Allergan, Cipla Inc..
The transdermal testosterone market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Transdermal Testosterone Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Transdermal Testosterone Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Transdermal Testosterone Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Transdermal Testosterone Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Transdermal Testosterone Market Size & Forecast, 2018-2028
4.5.1 Transdermal Testosterone Market Size and Y-o-Y Growth
4.5.2 Transdermal Testosterone Market Absolute $ Opportunity
Chapter 5 Global Transdermal Testosterone Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Transdermal Testosterone Market Size Forecast by Type
5.2.1 Gel
5.2.2 Patch
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Transdermal Testosterone Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Transdermal Testosterone Market Size Forecast by Applications
6.2.1 Primary Hypogonadism
6.2.2 Hypogonadotropic Hypogonadism
6.2.3 Late-Onset Hypogonadism
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Transdermal Testosterone Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Transdermal Testosterone Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Transdermal Testosterone Analysis and Forecast
9.1 Introduction
9.2 North America Transdermal Testosterone Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Transdermal Testosterone Market Size Forecast by Type
9.6.1 Gel
9.6.2 Patch
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Transdermal Testosterone Market Size Forecast by Applications
9.10.1 Primary Hypogonadism
9.10.2 Hypogonadotropic Hypogonadism
9.10.3 Late-Onset Hypogonadism
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Transdermal Testosterone Analysis and Forecast
10.1 Introduction
10.2 Europe Transdermal Testosterone Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Transdermal Testosterone Market Size Forecast by Type
10.6.1 Gel
10.6.2 Patch
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Transdermal Testosterone Market Size Forecast by Applications
10.10.1 Primary Hypogonadism
10.10.2 Hypogonadotropic Hypogonadism
10.10.3 Late-Onset Hypogonadism
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Transdermal Testosterone Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Transdermal Testosterone Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Transdermal Testosterone Market Size Forecast by Type
11.6.1 Gel
11.6.2 Patch
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Transdermal Testosterone Market Size Forecast by Applications
11.10.1 Primary Hypogonadism
11.10.2 Hypogonadotropic Hypogonadism
11.10.3 Late-Onset Hypogonadism
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Transdermal Testosterone Analysis and Forecast
12.1 Introduction
12.2 Latin America Transdermal Testosterone Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Transdermal Testosterone Market Size Forecast by Type
12.6.1 Gel
12.6.2 Patch
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Transdermal Testosterone Market Size Forecast by Applications
12.10.1 Primary Hypogonadism
12.10.2 Hypogonadotropic Hypogonadism
12.10.3 Late-Onset Hypogonadism
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Transdermal Testosterone Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Transdermal Testosterone Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Transdermal Testosterone Market Size Forecast by Type
13.6.1 Gel
13.6.2 Patch
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Transdermal Testosterone Market Size Forecast by Applications
13.10.1 Primary Hypogonadism
13.10.2 Hypogonadotropic Hypogonadism
13.10.3 Late-Onset Hypogonadism
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Transdermal Testosterone Market: Competitive Dashboard
14.2 Global Transdermal Testosterone Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AbbVie
14.3.2 Teva
14.3.3 Perrigo
14.3.4 Endo Pharmaceuticals
14.3.5 Acerus Pharmaceuticals
14.3.6 Lupin
14.3.7 Dr. Reddy's Laboratories
14.3.8 Upsher-Smith Laboratories
14.3.9 Allergan
14.3.10 Cipla Inc.
